HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Matthew K Ito Selected Research

lovastatin-niacin combination

3/2002Lovastatin and extended-release niacin combination product: the first drug combination for the management of hyperlipidemia.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Matthew K Ito Research Topics

Disease

12Dyslipidemias (Dyslipidemia)
11/2015 - 03/2002
11Cardiovascular Diseases (Cardiovascular Disease)
05/2020 - 07/2006
7Coronary Disease (Coronary Heart Disease)
10/2012 - 03/2002
5Hyperlipoproteinemia Type II (Familial Hypercholesterolemia)
01/2017 - 05/2011
4Hypertriglyceridemia
10/2015 - 11/2002
4Atherosclerosis
10/2015 - 09/2005
4Hyperlipidemias (Hyperlipidemia)
08/2013 - 03/2002
4Metabolic Syndrome (Dysmetabolic Syndrome X)
09/2005 - 03/2002
3Hypercholesterolemia
01/2017 - 10/2007
3Coronary Artery Disease (Coronary Atherosclerosis)
10/2015 - 09/2002
3Myalgia
01/2014 - 03/2013
3Flushing
03/2012 - 03/2002
2Inflammation (Inflammations)
12/2015 - 07/2006
2Homozygous Familial Hypercholesterolemia
10/2015 - 10/2007
2Hypertension (High Blood Pressure)
03/2015 - 11/2013
1Rheumatoid Arthritis
11/2015
1Inborn Genetic Diseases (Disease, Hereditary)
10/2015
1Pancreatitis
10/2015
1Heart Diseases (Heart Disease)
05/2015
1Diabetes Mellitus
03/2015
1Chronic Disease (Chronic Diseases)
11/2013
1Muscular Diseases (Myopathy)
10/2012
1Hypoalphalipoproteinemias (Hypoalphalipoproteinemia)
02/2011
1Atherosclerotic Plaque (Atheroma)
07/2006
1Hyperglycemia
09/2005

Drug/Important Bio-Agent (IBA)

17LipidsIBA
01/2017 - 03/2002
14CholesterolIBA
01/2017 - 03/2002
13Hydroxymethylglutaryl-CoA Reductase Inhibitors (HMG-CoA Reductase Inhibitors)IBA
05/2020 - 07/2006
9LDL CholesterolIBA
05/2020 - 09/2003
9oxidized low density lipoproteinIBA
05/2020 - 09/2002
9Niacin (Nicotinic Acid)FDA LinkGeneric
10/2015 - 03/2002
7HDL CholesterolIBA
11/2015 - 09/2002
4Triglycerides (Triacylglycerol)IBA
10/2015 - 09/2002
4Lipoproteins (Lipoprotein)IBA
10/2015 - 10/2007
3Fibric Acids (Fibrates)IBA
10/2015 - 09/2002
2Pharmaceutical PreparationsIBA
10/2015 - 03/2002
2Omega-3 Fatty Acids (Omega 3 Fatty Acids)IBA
10/2015 - 08/2011
2ApolipoproteinsIBA
03/2015 - 10/2007
2Ezetimibe (Zetia)FDA Link
10/2012 - 11/2002
2Adenosine Triphosphate (ATP)IBA
02/2004 - 09/2003
1evolocumabIBA
01/2017
1bococizumabIBA
01/2017
1alirocumabIBA
01/2017
1PCSK9 InhibitorsIBA
01/2017
1Monoclonal AntibodiesIBA
01/2017
1LDL Receptors (LDL Receptor)IBA
10/2015
1red yeast riceIBA
03/2013
1Fish OilsIBA
08/2011
1Antisense OligonucleotidesIBA
10/2007
1mipomersenIBA
10/2007
1Coenzyme A (CoA)IBA
07/2006
1Oxidoreductases (Dehydrogenase)IBA
07/2006
1Glucose (Dextrose)FDA LinkGeneric
09/2005
1HDL LipoproteinsIBA
09/2002
1LDL Lipoproteins (beta Lipoproteins)IBA
09/2002
1Lovastatin (Mevacor)FDA LinkGeneric
03/2002
1Generic DrugsIBA
03/2002
1lovastatin-niacin combinationFDA Link
03/2002
1Drug CombinationsIBA
03/2002

Therapy/Procedure

13Therapeutics
01/2017 - 09/2002
2Drug Therapy (Chemotherapy)
03/2015 - 09/2014
2Secondary Prevention
10/2012 - 03/2002
1Contraindications
01/2017